At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Dronabinol and Palmitoylethanolamidedrug
Likely dose
Dronabinol and Palmitoylethanolamide 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Examining the Efficacy of a Therapeutic Combination of Dronabinol (Synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Tourette Syndrome
In Brief
A Phase 2 clinical trial evaluating Dronabinol and Palmitoylethanolamide for Tourette Syndrome. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This is an investigator-initiated proof of concept study with the purpose to examine the safety, tolerability and feasibility of Dronabinol (synthetic Δ9-THC) and PEA for the treatment of adults with Tourette syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette Syndrome
CountriesUnited States
CollaboratorsNeurothera Labs Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
First PostedFeb 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedFeb 28, 2017
Enrollment StartFeb 1, 2017
Primary CompletionJun 28, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.3 years ago
Interventions
Dronabinol and Palmitoylethanolamidedrug
Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.